Tüdőrák: vizsgálatok itt: Kína
1144 trials · From ClinicalTrials.gov, checked 2026. november 16.. Ask the study team whether a trial fits you.
- 1. fázisTaking peopleStudy of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 100
- Run by
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
See details and how to joinNCT07231445 - 2. fázisNot yet taking people in KínaGFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 90
- Run by
- Genfleet Therapeutics (Shanghai) Inc.
See details and how to joinNCT07554859 - No phaseTaking peopleSub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
- Where
- Wuhan
- Életkor
- 18 év and over
- People
- 26
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07552467 - 1/2. fázisTaking peopleA Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
- Where
- Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Nanchang, Shanghai, Taizhou, Wuhan
- Életkor
- 18 év to 75 év
- People
- 440 worldwide
- Run by
- Tyligand Pharmaceuticals (Suzhou) Limited
See details and how to joinNCT06385925 - 2. fázisTaking peopleTislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC
- Where
- Jincheng, Jinzhong, Taiyuan
- Életkor
- 18 év to 80 év
- People
- 40
- Run by
- Second Hospital of Shanxi Medical University
See details and how to joinNCT06536868 - No phaseTaking peopleSleeve Lobectomy for Lung Cancer in Minimally Invasive Surgical Techniques
- Where
- Hangzhou, Shanghai
- Életkor
- 18 év and over
- People
- 450
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06687408 - 1. fázisNot yet taking people in KínaA Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
- Where
- Changzhou, Harbin, Shanghai, Shenyang, Taizhou, Wuhan, Zhengzhou
- Életkor
- 18 év and over
- People
- 33
- Run by
- Shanghai Best-Link Bioscience, LLC
See details and how to joinNCT07550842 - 2. fázisNot yet taking people in KínaZorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 38
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07551414 - 3. fázisCsak meghívásosEfficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.
- Where
- Guangzhou
- Életkor
- 18 év and over
- People
- 327
- Run by
- Avistone Biotechnology Co., Ltd.
See details and how to joinNCT06281964 - 2. fázisTaking peoplectDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 80
- Run by
- Sun Yat-sen University
See details and how to joinNCT06426511 - No phaseTaking peopleDouble-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
- Where
- Nanchang
- Életkor
- 18 év to 99 év
- People
- 30
- Run by
- Second Affiliated Hospital of Nanchang University
See details and how to joinNCT07398599 - 2. fázisTaking peopleA Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
- Where
- Tianjin
- Életkor
- 18 év to 75 év
- People
- 25
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07548060 - 2. fázisNot yet taking people in KínaEfficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis
- Where
- Yiwu
- Életkor
- 18 év and over
- People
- 27
- Run by
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07545213 - 2. fázisTaking peopleNeoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 36
- Run by
- Sun Yat-sen University
See details and how to joinNCT03872661 - 2. fázisTaking peopleNeoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 120
- Run by
- Sun Yat-sen University
See details and how to joinNCT06563999 - No phaseTaking peopleRATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC
- Where
- Fuzhou, Guangzhou, Nanjing, Qingdao, Shanghai, Shenzhen, Tianjing
- People
- 100 worldwide
- Run by
- Shanghai Chest Hospital
See details and how to joinNCT07541521 - 1/2. fázisTaking peopleA Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer
- Where
- Hangzhou, Shanghai
- Életkor
- 18 év to 75 év
- People
- 324
- Run by
- Jiangsu HengRui Medicine Co., Ltd.
See details and how to joinNCT05482568 - 3. fázisTaking peopleA Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 720
- Run by
- Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT06838273 - No phaseNot yet taking people in KínaIparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer
- Where
- Xi'an
- Életkor
- 18 év and over
- People
- 28
- Run by
- Tang-Du Hospital
See details and how to joinNCT07538193 - 1. fázisNot yet taking people in KínaA Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver Function
- Where
- Qingdao, Xiamen, Zhengzhou
- Életkor
- 18 év to 65 év
- People
- 24
- Run by
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
See details and how to joinNCT07538973 - 2. fázisTaking peopleTrilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)
- Where
- Xiamen
- Életkor
- 18 év to 75 év
- People
- 49
- Run by
- The First Affiliated Hospital of Xiamen University
See details and how to joinNCT06992739 - No phaseTaking peopleDownstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC
- Where
- Fuzhou, Guangzhou, Nanjing, Qingdao, Shanghai, Shenzhen, Tianjing
- People
- 200 worldwide
- Run by
- Shanghai Chest Hospital
See details and how to joinNCT07528066 - 2. fázisTaking peopleMicrowave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 20
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07528274 - 1. fázisTaking peoplePhase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
- Where
- Changchun, Chengdu, Fuzhou, Shandong, Shanghai, Zhengzhou
- Életkor
- 18 év and over
- People
- 304 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT04686305 · EU 2023-504949-31-00 - No phaseTaking peopleSegmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm
- Where
- Hangzhou, Hefei, Huzhou, Jinan, Nantong, Nanyang, Ningbo, Shanghai, Xuzhou, Yancheng
- Életkor
- 20 év to 79 év
- People
- 690
- Run by
- Shanghai Pulmonary Hospital, Shanghai, China
See details and how to joinNCT04937283